Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27779786 | 0.79 | CA12 (0.35) | CA12CA7CA14MAPTALDH1A1 | |
| SCHEMBL5451713 | 0.79 | ALDH1A1 (0.35) | MAPTALDH1A1LMNAHPGDRAB9A | |
| SCHEMBL5934028 | 0.77 | USP2 (0.35) | CA12CA7CA14MAPTALDH1A1 | |
| SCHEMBL28058020 | 0.76 | ANPEP (0.35) | CA12CA7CA14MAPTALDH1A1 | |
| SCHEMBL5452862 | 0.76 | ALDH1A1 (0.33) | MAPTALDH1A1LMNAHPGDRAB9A | |
| SCHEMBL1395709 | 0.76 | LMNA (0.41) | CA12CA7CA14MAPTALDH1A1 | |
| SCHEMBL7427319 | 0.75 | LMNA (0.38) | MAPTALDH1A1LMNAHPGDRAB9A | |
| SCHEMBL29233270 | 0.75 | LMNA (0.40) | CA12CA7CA14MAPTALDH1A1 | |
| SCHEMBL31412188 | 0.75 | GLA (0.44) | MAPTALDH1A1LMNAHPGDRAB9A | |
| SCHEMBL1255349 | 0.73 | ALDH1A1 (0.34) | CA12CA7CA14MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5968548-A | Use of liposome encapsulated cirprofloxacin as an immunotherapeutic drug | MINISTER OF NATIONAL DEFENCE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) | 1999-10-19 | — | — | US | disclosed |